Carbazochrome is a synthetic derivative of adrenochrome, primarily used as a systemic hemostatic agent. It acts by stabilizing capillary walls, reducing vascular permeability, and promoting platelet aggregation, thereby controlling capillary bleeding. It is not a vasoconstrictor and does not affect blood pressure or heart rate. In the Indian market, it is widely prescribed for various bleeding disorders, particularly in surgical and gynecological settings.
Adult: 5mg (one tablet) two to three times daily. In acute bleeding, 5mg three times daily. Maximum daily dose: 15mg.
Note: Oral administration. Tablet should be swallowed whole with a glass of water, with or without food. For best results, administer at regular intervals.
Carbazochrome exerts its hemostatic effect by reducing the abnormal permeability and fragility of capillaries. It acts on the capillary endothelium, strengthening the intercellular cement substance. This reduces the leakage of blood components through the capillary walls. It also promotes platelet adhesion and aggregation at the site of capillary injury, facilitating clot formation without affecting the coagulation cascade directly.
Pregnancy: Category C: Animal reproduction studies have not been conducted. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Used in India for pregnancy-related bleeding like threatened abortion under specialist care.
Driving: Unlikely to affect ability; however, if dizziness occurs, avoid driving or operating machinery.
| Anticoagulants (Warfarin, Acenocoumarol) | Theoretical antagonism of anticoagulant effect; monitor INR closely. | Moderate |
| Antiplatelets (Aspirin, Clopidogrel) | May reduce the hemostatic efficacy of carbazochrome. | Moderate |
| Other hemostatic agents (Tranexamic acid, Etamsylate) | Additive hemostatic effect; use combination only under medical supervision. | Low |
Same composition (Carbazochrome (5mg)), different brands: